IS2494B - Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni - Google Patents
Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkniInfo
- Publication number
- IS2494B IS2494B IS5568A IS5568A IS2494B IS 2494 B IS2494 B IS 2494B IS 5568 A IS5568 A IS 5568A IS 5568 A IS5568 A IS 5568A IS 2494 B IS2494 B IS 2494B
- Authority
- IS
- Iceland
- Prior art keywords
- morpholinol
- treatment
- sexual dysfunction
- sexual
- dysfunction
- Prior art date
Links
- OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 title 1
- 201000001880 Sexual dysfunction Diseases 0.000 title 1
- 231100000872 sexual dysfunction Toxicity 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801230.5A GB9801230D0 (en) | 1998-01-21 | 1998-01-21 | Pharmaceutically active morpholinol |
| US7218098P | 1998-01-22 | 1998-01-22 | |
| PCT/US1999/001134 WO1999037305A1 (en) | 1998-01-21 | 1999-01-20 | Pharmaceutically active morpholinol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IS5568A IS5568A (is) | 2000-07-20 |
| IS2494B true IS2494B (is) | 2009-02-15 |
Family
ID=26312986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS5568A IS2494B (is) | 1998-01-21 | 2000-07-20 | Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6274579B1 (is) |
| EP (2) | EP1047428B1 (is) |
| JP (1) | JP2002501025A (is) |
| KR (1) | KR100568063B1 (is) |
| CN (2) | CN1203858C (is) |
| AP (1) | AP1229A (is) |
| AT (1) | ATE365042T1 (is) |
| AU (1) | AU755536B2 (is) |
| BR (1) | BR9907203A (is) |
| CA (1) | CA2318268A1 (is) |
| CY (1) | CY1106828T1 (is) |
| DE (1) | DE69936335T2 (is) |
| DK (1) | DK1047428T3 (is) |
| EA (1) | EA002410B1 (is) |
| EE (1) | EE04452B1 (is) |
| ES (1) | ES2288012T3 (is) |
| HR (2) | HRP20000494B1 (is) |
| HU (1) | HUP0100900A3 (is) |
| ID (1) | ID26334A (is) |
| IL (2) | IL161942A0 (is) |
| IS (1) | IS2494B (is) |
| NO (2) | NO326878B1 (is) |
| NZ (3) | NZ505809A (is) |
| PL (1) | PL193622B1 (is) |
| PT (1) | PT1047428E (is) |
| SG (1) | SG115489A1 (is) |
| SK (1) | SK10912000A3 (is) |
| TR (1) | TR200002126T2 (is) |
| WO (1) | WO1999037305A1 (is) |
| YU (1) | YU67102A (is) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098206B2 (en) * | 1998-01-21 | 2006-08-29 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6998400B2 (en) * | 1998-01-22 | 2006-02-14 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| AU2349999A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmacological uses of pure (+) -bupropion |
| US6855820B2 (en) | 1999-01-20 | 2005-02-15 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6734213B2 (en) | 1999-01-20 | 2004-05-11 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| AU7750100A (en) * | 1999-10-13 | 2001-04-23 | Glaxo Group Limited | Method for the treatment of obesity |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| CA2365428C (en) * | 2000-12-21 | 2008-10-21 | Brasscorp Limited | Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing |
| US6979104B2 (en) | 2001-12-31 | 2005-12-27 | R.J. Doran & Co. LTD | LED inspection lamp |
| MXPA04011203A (es) * | 2002-05-17 | 2005-07-14 | Univ Duke | Metodo para tratar la obesidad. |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| GB0219687D0 (en) * | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| DE60324685D1 (de) * | 2002-08-23 | 2008-12-24 | Lilly Co Eli | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren |
| WO2004096201A1 (en) | 2003-04-29 | 2004-11-11 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| GB0325055D0 (en) * | 2003-10-27 | 2003-12-03 | Smithkline Beecham Corp | New process |
| WO2005044809A1 (en) * | 2003-10-27 | 2005-05-19 | Smithkline Beecham Corporation | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof |
| GB0326148D0 (en) * | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| GB0327619D0 (en) * | 2003-11-27 | 2003-12-31 | Smithkline Beecham Corp | New use |
| EP1734955A2 (en) | 2004-01-13 | 2006-12-27 | Duke University | Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| EP1748776A1 (en) * | 2004-05-03 | 2007-02-07 | Duke University | Compositions for affecting weight loss |
| FI117283B (fi) | 2005-02-04 | 2006-08-31 | Kone Corp | Hissijärjestelmä |
| ES2761812T3 (es) | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composición y métodos de aumento de la sensibilidad a la insulina |
| EP1968603A4 (en) * | 2006-01-03 | 2013-01-16 | Algebra Inc | THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| KR20150082689A (ko) | 2006-11-09 | 2015-07-15 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| DK2089005T3 (da) | 2006-11-09 | 2010-07-19 | Orexigen Therapeutics Inc | Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag |
| US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| WO2010121022A1 (en) | 2009-04-15 | 2010-10-21 | Research Triangle Institute | Monoamine reuptake inhibitors |
| CN102724878A (zh) | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
| CA2800219C (en) | 2010-05-21 | 2019-03-12 | Research Triangle Institute | 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| EP2571858B1 (en) | 2010-05-21 | 2018-06-20 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| US9510405B2 (en) | 2011-06-30 | 2016-11-29 | Schneider Electric Industries Sas | Dual power SMPS for a modular lighting system |
| CN102670617B (zh) * | 2012-04-13 | 2013-03-20 | 湖南大学 | 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用 |
| HUE072188T2 (hu) | 2012-06-06 | 2025-10-28 | Nalpropion Pharmaceuticals Llc | Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| RU2763728C1 (ru) * | 2021-06-17 | 2021-12-30 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US170430A (en) * | 1875-11-30 | Improvement in furnaces for heating steel in tempering | ||
| GB8417170D0 (en) * | 1984-07-05 | 1984-08-08 | Wellcome Found | Heterocyclic pharmaceutical compounds |
| GB9108629D0 (en) | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
-
1999
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
-
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
-
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
-
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
-
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
-
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6303A (is) | Notkun retígabíns til meðhöndlunar á taugasjúkdómatengdum sársauka | |
| DK1047428T3 (da) | Anvendelse af morpholinol til behandlingen af seksualforstyrrelser | |
| GT199900013A (es) | Tratamiento de la disfuncion sexual femenina. | |
| IS6785A (is) | EP4 viðtakahindrar til meðhöndlunar á liðagigt | |
| NO20005255L (no) | Pyrazolpyrimidin-CGMPPDE5-inhibitorer for behandling av seksuell dysfunksjon | |
| IS5085A (is) | Nefholssamsetningar til meðhöndlunar á kynferðistruflunum | |
| DE60020327D1 (de) | Wasserbehandlungsvorrichtung | |
| DK1144395T3 (da) | 2-amino-benzoxazinon-derivater til behandling af fedme | |
| IS6195A (is) | Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki | |
| ID30276A (id) | Metode untuk mengobati gangguan-gangguan seksual | |
| DK1063990T3 (da) | Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser | |
| IS2261B (is) | Aðferð til framleiðslu á 5-sýanóþalíði | |
| NO20024775D0 (no) | Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
| NO995823D0 (no) | Terapeutisk middel for ereksjonsdysfunksjon | |
| NO20024776L (no) | Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte | |
| NO20024777D0 (no) | Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte | |
| DK1008558T3 (da) | Fremgangsmåde til behandling af organisk spildevand | |
| IS7136A (is) | Aðferð til meðhöndlunar á svefnleysi á frumstigi | |
| IT1306165B1 (it) | Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi. | |
| NO20013146L (no) | Middel for behandling av synscellefunksjonsforstyrrelse | |
| GB0130219D0 (en) | Compounds for the treatment of sexual dysfunction | |
| NO20013596D0 (no) | Slambehandling | |
| DE50009813D1 (de) | Kombinationpräparat zur behandlung von sexueller dysfunktion | |
| DE60022086D1 (de) | Wasserbehandlung | |
| NO20022101D0 (no) | Peptider for behandling av erektil dysfunksjon |